Skip to main content
Divisions
Molecular diagnostics and distributed qPCR solutions.
Complete PCR solutions for molecular diagnostics.
Customised NGS for next-generation molecular insights.
Technologies
Instruments
Miniaturised qPCR devices with superior performance
Software Solutions
Cloud-based platform driven by artificial intelligence for advanced operations
Reagents
Deep multiplexing solutions and innovative reagents for all use cases
About us
Vision & Values
Our identity and the principles that guide the Group.
Numbers and Certifications
Reliability, performance and standards that define our work.
Leadership
The management team leading Helyx Industries.
About Helyx
The history, evolution and culture of our Group.
Insights
See all Insights
22 December 2025 | Vision & Strategy
Helyx Industries: one group, three divisions. From distributed qPCR to tailor-made NGS
Helyx Industries was born out of a paradigm shift: from Ulisse Biomed to an integrated industrial group with three complementary divisions — Hyris, Vytro and Mytho — covering the entire spectrum of molecular diagnostics, from distributed qPCR to customised NGS. This article recounts the transformation, the new structure and the vision that now guides Helyx's evolution.
17 November 2025 | Biotech and Diagnostic Innovation
Multiplex PCR diagnosis for HPV: New frontiers
Multiplex PCR is revolutionising HPV screening thanks to its ability to identify multiple high-risk genotypes in a single test, improving sensitivity and accuracy. Recent evidence confirms the clinical value of self-sampling in enhancing screening adherence. A combined approach could significantly reduce the incidence of cervical cancer.
News
Press releases
19 December 2025
Comunicazione di variazione del capitale sociale, deposito attestazione ai sensi dell'art. 2444 C.C. e statuto aggiornato
Press releases
12 December 2025
Efficacia del cambio di denominazione sociale da "Ulisse Biomed S.p.A." a "Helyx Industries S.p.A."
Press releases
05 December 2025
Maturazione della seconda trance del Piano Stock Grant 2024-2028
Press releases
02 December 2025
L'Assemblea degli azionisti ha approvato la proposta di variazione della denominazione sociale da "Ulisse Biomed S.p.A." a "Helyx Industries S.p.A."
Investors
Helyx Industries is an industrial group active in the field of genetics. It has proprietary technologies and processes for complete and integrated solutions in molecular biology, from PCR to NGS. Through its divisions, it offers its solutions directly to diagnostic laboratories and hospitals or provides its services to diagnostic and industrial partners. Helyx Industries is listed on Euronext Growth in Milan.
Read more
Contact us
IT
EN
IT
EN
Divisions
Molecular diagnostics and distributed qPCR solutions.
Hyris System™
Agrifood & Nutraceuticals Catalogue
Development and OEM services
Complete PCR solutions for molecular diagnostics.
Human Health Catalogue
Customised NGS for next-generation molecular insights.
Customised NGS panels
Compatible areas & technologies
Technologies
Instruments
Miniaturised qPCR devices with superior performance
bCUBE™
bGATE™
Software Solutions
Cloud-based platform driven by artificial intelligence for advanced operations
bAPP™
Reagents
Deep multiplexing solutions and innovative reagents for all use cases
Sagitta™
Stable multiplex reagents
About Us
Vision & Values
Our identity and the principles that guide the Group.
Vision
Mission
Numbers and Certifications
Reliability, performance and standards that define our work.
Facts and Figures
Certifications
Leadership
The management team leading Helyx Industries.
People
About Helyx
The history, evolution and culture of our Group.
Our History
Timeline
Insights
News
Updates & announcements
Commercial news announced by Helyx Industries.
Read all
Press releases
Regulated and price-sensitive press releases.
Read all
Scientific Publications
Research, studies and published scientific papers.
Read all
Investors
Helyx Industries
Helyx Industries is an integrated biotech group with proprietary technologies that develops diagnostic solutions, focusing on public health, distributed diagnostics and molecular innovation.
Download Pitch Deck
Overview
Corporate Governance
Information for shareholders
Financial data
Press releases
Financial calendar
Shareholders' meeting
Analyst Coverage
Warrant
Internal dealing
Investment Agreement with GCF
Concluded extraordinary transactions
IPO
Investor Relations Contacts
Contacts
21 December, 2023
Press releases
L’Assemblea degli Azionisti approva l’operazione di reverse take-over e l’aumento di capitale in natura a servizio della stessa. Approvate altresì la ratifica della nomina per cooptazione dell’amministratrice indipendente e le modifiche statutarie.
Link
Prev
Next
Back to News frontpage
Prev
Next
19 December 2025
Comunicazione di variazione del capitale sociale, deposito attestazione ai sensi dell'art. 2444 C.C. e statuto aggiornato
CONTINUE TO READING
12 December 2025
Efficacia del cambio di denominazione sociale da "Ulisse Biomed S.p.A." a "Helyx Industries S.p.A."
CONTINUE TO READING
05 December 2025
Maturazione della seconda trance del Piano Stock Grant 2024-2028
CONTINUE TO READING
02 December 2025
L'Assemblea degli azionisti ha approvato la proposta di variazione della denominazione sociale da "Ulisse Biomed S.p.A." a "Helyx Industries S.p.A."
CONTINUE TO READING
01 December 2025
Rinvio assemblea straordinaria in seconda convocazione
CONTINUE TO READING
28 November 2025
Concluso l'aumento di capitale riservato deliberato dal Consiglio di Amministrazione il 13 novembre 2025, Comunicazione di variazione del capitale sociale, Deposito attestazione ai sensi dell'art. 2444 C.C. e statuto aggiornato
CONTINUE TO READING
24 November 2025
Ulisse Biomed S.p.A. riceve un ordine significativo per la fornitura di prodotti in ambito NGS. Rivista al rialzo la guidance di fatturato previsto per l'esercizio 2025
CONTINUE TO READING
21 November 2025
Sottoscritto per Euro 537.200 l'aumento di capitale sociale deliberato dal Consiglio di Amministrazione in data 13 novembre 2025
CONTINUE TO READING
15 November 2025
Convocazione assemblea straordinaria degli azionisti e deposito documentazione assembleare
CONTINUE TO READING
13 November 2025
Il Consiglio di Amministrazione esercita la delega ad aumentare il capitale sociale e convoca l'assemblea straordinaria degli azionisti per la variazione della denominazione sociale
CONTINUE TO READING
19 December 2025
Comunicazione di variazione del capitale sociale, deposito attestazione ai sensi dell'art. 2444 C.C. e statuto aggiornato
CONTINUE TO READING
12 December 2025
Efficacia del cambio di denominazione sociale da "Ulisse Biomed S.p.A." a "Helyx Industries S.p.A."
CONTINUE TO READING
05 December 2025
Maturazione della seconda trance del Piano Stock Grant 2024-2028
CONTINUE TO READING
02 December 2025
L'Assemblea degli azionisti ha approvato la proposta di variazione della denominazione sociale da "Ulisse Biomed S.p.A." a "Helyx Industries S.p.A."
CONTINUE TO READING
01 December 2025
Rinvio assemblea straordinaria in seconda convocazione
CONTINUE TO READING
28 November 2025
Concluso l'aumento di capitale riservato deliberato dal Consiglio di Amministrazione il 13 novembre 2025, Comunicazione di variazione del capitale sociale, Deposito attestazione ai sensi dell'art. 2444 C.C. e statuto aggiornato
CONTINUE TO READING
24 November 2025
Ulisse Biomed S.p.A. riceve un ordine significativo per la fornitura di prodotti in ambito NGS. Rivista al rialzo la guidance di fatturato previsto per l'esercizio 2025
CONTINUE TO READING
21 November 2025
Sottoscritto per Euro 537.200 l'aumento di capitale sociale deliberato dal Consiglio di Amministrazione in data 13 novembre 2025
CONTINUE TO READING
15 November 2025
Convocazione assemblea straordinaria degli azionisti e deposito documentazione assembleare
CONTINUE TO READING
13 November 2025
Il Consiglio di Amministrazione esercita la delega ad aumentare il capitale sociale e convoca l'assemblea straordinaria degli azionisti per la variazione della denominazione sociale
CONTINUE TO READING
